CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

Baudry, Camille, Coste, Joël, Bou Khalil, Roula, Silvera, Stéphane, Guignat, Laurence, Guibourdenche, Jean, Abbas, Halim, Legmann, Paul, Bertagna, Xavier, Bertherat, Jérôme · 2012 · European Journal of Endocrinology

Abstract

Context: Alternatives to transsphenoidal pituitary surgery may be required in Cushing's disease (CD) as a first- or second-line treatment. Mitotane is a potent anti-cortisolic drug but has been rarely investigated in the treatment of CD. Objective: Evaluation of the efficacy and tolerance of mitotane in CD patients. Design and setting: Retrospective analysis of 76 patients treated with mitotane from 219 patients diagnosed with CD between 1993 and 2009 in a single center. Main outcome measure: Remission was defined as normalization of 24-h urinary free cortisol (24-h-UFC). Results: Remission was achieved in 48 (72%) of the 67 long-term treated patients, after a median time of 6.7 (5.2–8.2) months. Mean plasma mitotane concentration at the time of remission was 10.5±8.9 mg/l, with a mean daily dose of 2.6±1.1 g. A negative linear relationship was observed between plasma mitotane concentration and 24-h-UFC ( P <0.0001). Seventeen of 24 (71%) patients with durable remission subsequently experienced recurrence, after a median time of 13.2 (5.0–67.9) months. At the time of treatment discontinuation, ACTH concentration was statistically associated with a lower recurrence probability (hazard ratios 0.57 (0.32–1.00), P =0.05). Intolerance leading to treatment discontinuation occurred in 19 patients (29%). A pituitary adenoma became identifiable during mitotane treatment in 12 (25%) of the 48 patients with initial negative pituitary imaging allowing subsequent transsphenoidal surgery. Conclusion: Mitotane is useful at different stages of CD. Mitotane dose adjustment based on plasma concentration monitoring and side effects could control hypercortisolism in the majority of CD patients.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-12-0358

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Research works printed but not linked: 2

  1. 2001, 92, 1385, 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2 · DOI · Paper page
  2. MAHER, 1992, QJM, 84, 671

Cited by

See all 187

Metadata

Authors
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital Cochin (FR)
Venue
European Journal of Endocrinology
Published
2012-10
Volume
167
Issue
4
Pages
473-481
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2160063358
Cited by
187
References
47
Citations by year
2026: 6 · 2025: 8 · 2024: 14 · 2023: 11 · 2022: 17 · 2021: 8 · 2020: 13 · 2019: 17 · 2018: 19 · 2017: 12 · 2016: 14 · 2015: 17 · 2014: 14 · 2013: 13 · 2012: 2
FWCI
11.81
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
Cushing's disease, mitotane, hypercortisolism, remission, urinary free cortisol, treatment intolerance, recurrence, ACTH, pituitary adenoma, transsphenoidal surgery, dose adjustment
MeSH terms
Adolescent, Adult, Aged, Female, Hormone Antagonists, Humans, Male, Middle Aged, Mitotane, Retrospective Studies, Cohort Studies, Treatment Outcome, Antineoplastic Agents, Hormonal, Pituitary ACTH Hypersecretion, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. https://app.cochat.ai/papers/10.1530/eje-12-0358
The paper
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012). Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. European Journal of Endocrinology. https://doi.org/10.1530/eje-12-0358

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.